Archean Chemical FY26: Bromine Burning, Salt Stalling

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

The company sold salt and bromine into an industrial thaw that never came.

FY26 revenue inched up 3% to ₹1,081 Cr, but the gain belonged entirely to salt; bromine revenue fell 13% to ₹3,084 Cr, buckling under global oversupply and demand collapse in end-user segments. Profits tanked 41% year-on-year—PAT slumped from ₹162 Cr to ₹107 Cr.

The cyclone that hammered Kutch in Q2 wiped ₹40 Cr of salt inventory. Post-cyclone, logistics costs jumped ₹14-15 Cr in Q4 alone as government road repairs doubled the distance to port. The US-Iran conflict spiked freight costs 18-20%, adding sandpaper to already-fraying margins.

Subsidiary Acume (bromine derivatives) stayed deep in the red—₹81 Cr revenue, ₹98 Cr EBITDA loss. The cash register still has ₹55 Cr and an untapped ₹165 Cr credit line, but that cushion is shrinking into a ₹2,067 Cr semiconductor fab with no switchboard in sight.

Plenty of optionality on display here. None of it lives tomorrow.

2. Introduction

Archean Chemical is India’s largest bromine exporter and a top industrial-salt producer, born from Hajipir in Gujarat’s Rann of Kutch—a sprawl of brine pools and salt pans where nature does most of the work.

For seven years post-IPO (November 2022, ₹805 Cr raise), the company rode a bromine boom that vaulted prices 2x between 2018 and 2023. By then, executives were drunk on scale. They doubled bromine capacity to 42,500 MTPA, spun up a derivatives plant (Acume Chemicals), bought an oilfield mud-chemical NCLT shell (Idealis), and then went scorched-earth into semiconductors: a ₹2,067 Cr silicon-carbide fab with 75% government co-funding.

But the boom crested in March 2023. Bromine realisations have fallen 35% since. Industrial salt sits in a commodity straightjacket. Acume’s derivatives ramp is a three-year crawl. Idealis is still begging for state permits. The semiconductor project is barely off the page.

Management calls FY26 “skewed with headwinds outweighing positives.” That’s the second year running.

3. Business Model: WTF Do They Even Do?

The core is surgical—bromine and industrial salt, extracted from brine, sent to 77 customers (41 domestic, 36 export) across 13 countries.

Industrial Salt (70% of FY26 revenue) flows to chlor-alkali plants (caustic soda, soda ash), textile mills, oil rigs, food makers, and water treaters. Installed capacity is 6 MMTPA; FY26 output hit 4.25 MT (annualised to 4.2 MT reported). Sojitz Corporation, the Japanese trading house, sucks up 50-55% of salt volumes via a 2.2 MT annual commitment—a long-term moat that is also a single-point fail. Solar evaporation of seawater does the lifting; feedstock costs close to zero. The real cost is land lease (Hajipir brine fields sit on Gujarat state-owned land, renewed via MOU dating to 2008) and logistics once salt leaves the pan.

Bromine (30% of FY26 revenue) is extracted from the same brine, shipped to pharma, agrochemical, flame-retardant, water-treatment, and energy-storage shops. Installed capacity 42,500 MTPA; FY26 volume was just 13,263 MT (used ~31% of merchant capacity). Realisations have collapsed. Spot prices spiked mid-Q4 (management cited RMB 70k-80k, ~US$8-9/kg) but “softened” when the customer chain couldn’t pass the cost forward. Management runs 70% on long-term contracts (annual repricing), 20-30% on spot. When prices rise, the LTC lag bites hard. When they fall, the company benefits. FY26 caught the downslope.

Sulphate of Potash (SOP): chloride-free fertilizer, ₹1.3 MMTPA installed, ₹3.5 Cr revenue in FY26—basically nothing. Process keeps failing. The company invested in German tech to iron out mineral yield. Plant trials are pencilled for Q1 FY27. Meaningful revenue by H2 FY27.

Bromine Derivatives (Acume, 7% of consolidated revenue) manufactures clear brine fluids (CBF), PTA catalysts, and flame retardants at Jhagadia. Q4 FY26 revenue: ₹24 Cr at 45% utilisation. The losses are legendary—₹98 Cr EBITDA negative for the full year. Management expects breakeven in FY27 “supported by improved capacity utilisation”—meaning 45% was the bottom, a comforting thought and probably a guess. Products launched in campaign mode; new alkali bromides on the roadmap for 1H FY27.

Oilfield Mud Chemicals (Idealis): acquired NCLT shell Oren Hydrocarbon for ₹77 Cr in January 2024. Three of six plants are now live. The Gujarat unit (bentonite) is “production-ready but awaiting state approvals”—a bottleneck the company frames as an interpretation dispute with Gujarat authorities. Demand is “fairly muted.” First real revenue push expected H2 FY27 if permits land.

The business is geographic and product-diverse on the surface (41 domestic accounts + 36 overseas; salt, bromine, SOP, derivatives, mud chemicals). In truth, it’s bromine + salt, with 77% of revenue from exports and Sojitz alone worth 25% of total topline. Customer concentration is explicit and structural—top 10 account for 77% of revenue, top 20 for 87%.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Narrative: FY26 revenue inched up 3% (₹1,042 Cr → ₹1,108 Cr) on salt recovery. Salt segment revenue grew 10% to ₹729 Cr (4.25 MT, +22% volume). But bromine revenue cratered 13% to ₹308 Cr on volume decline (-25% to 13,263 MT) and realisation pressure. Acume added ₹81 Cr (up 202% YoY) but burned ₹98 Cr in EBITDA. Idealis contributed ₹17 Cr (immaterial).

EBITDA fell to ₹265 Cr (FY25: ₹308 Cr), margin contracting from 30% to 24%. Operating profit was ₹227 Cr; after ₹93 Cr depreciation, ₹26 Cr finance cost, ₹42 Cr tax, PAT landed at ₹105 Cr—a 35% drop.

Q4 alone was brutal. Revenue ₹301 Cr (-13% YoY), EBITDA ₹49 Cr (-34% YoY), margin 21.8% (down from 27%). Q4 EPS was ₹0.98 (down from ₹4.34 in Q4 FY25). Logistics costs